Evidence map›Paper›PMID 42244019›Full record

ArticleJournal of cannabis research2026

Who is at risk? Core mental health symptoms and problematic cannabis use in Germany.

Eva-Maria Krowartz, Larissa Schwarzkopf, Sally Olderbak, Stefanie J Klug, Gabriele Koller, Esther Neumeier, Elena Gomes de Matos, Eva Hoch

Abstract read
In one paragraph

Article in Journal of cannabis research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eva-Maria KrowartzDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany. krowartz@ift.de.ORCID http://orcid.org/0009-0004-9443-9635
Larissa SchwarzkopfIFT Institut Für Therapieforschung, Centre for Mental Health and Addiction Research, Munich, Germany.ORCID http://orcid.org/0000-0002-9402-7700
Sally OlderbakDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0001-6133-0458
Stefanie J KlugTUM School of Medicine and Health, Chair of Epidemiology, Technical University of Munich, Munich, Germany.ORCID http://orcid.org/0000-0003-3523-1362
Gabriele KollerDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
Esther NeumeierIFT Institut Für Therapieforschung, Centre for Mental Health and Addiction Research, Munich, Germany.ORCID http://orcid.org/0000-0002-4397-9349
Elena Gomes de MatosIFT Institut Für Therapieforschung, Centre for Mental Health and Addiction Research, Munich, Germany.ORCID http://orcid.org/0000-0002-9232-6707
Eva HochDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsCannabis is one of the most used psychoactive substances worldwide. This study presents nationally representative data on core mental health symptoms and other characteristics among individuals in Germany who used cannabis in the past 12 months, stratified into those with and without problematic cannabis use.

methodsData were drawn from the 10th wave (2021) of the Epidemiological Survey of Substance Abuse, a cross-sectional survey of adults aged 18-64 years living in private households in Germany. The analytic sample included 1,004 past-year cannabis users. Problematic cannabis use was assessed using the Severity of Dependence Scale with sex-specific cut-offs (≥ 2 for women, ≥ 4 for men). Core mental health symptoms were measured with the DIA-X-Core Screening Questionnaire and categorized into 0, 1-3, or ≥ 4 symptoms. Analyses were weighted to match the German population. Descriptive comparisons between individuals with and without problematic use employed χ

findingsAmong individuals with past-year cannabis use, 25.0% met criteria for problematic use. Compared with those without problematic use, these individuals were more likely to have a low educational level (27.2% vs. 10.8%), use cannabis weekly or almost daily (66.8% vs. 14.8%), begin use before age 15 (40.8% vs. 19.1%), currently use tobacco (73.1% vs. 49.7%), and report problematic amphetamine- (10.5% vs. 2.2%) and tobacco use (23.8% vs.14.0%). They were less likely to report no core mental health symptoms (12.7% vs. 25.3%) and more likely to report ≥ 4 symptoms (40.8% vs. 27.2%). Adjusted models showed that reporting ≥ 4 symptoms was positively associated with problematic use (aOR = 1.68; 95% CI [1.12-2.53]; p=.027), whereas having no symptoms was associated negatively (aOR = 0.41; 95% CI [0.23-0.73]; p=.006).

conclusionAmid changing cannabis laws in Germany, this study identifies risk factors for problematic use and highlights that core mental health symptoms are associated with problematic cannabis use. The findings underscore the importance of early screening and targeted prevention strategies.

Indexed as

CannabisCannabis dependenceCannabis use disorderCore symptomMental healthProblematic cannabis use

Identifiers

PMID42244019
PMCPMC13237940

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.